Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 20 Feb 2017
At a glance
- Drugs Dasatinib (Primary)
- Indications Cholangiocarcinoma
- Focus Therapeutic Use
- 16 Feb 2017 Status changed from recruiting to active, no longer recruiting.
- 09 Mar 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 05 May 2015 New trial record